U.S. flag

An official website of the United States government

NM_001134407.3(GRIN2A):c.306C>T (p.Asp102=) AND not provided

Germline classification:
Benign/Likely benign (2 submissions)
Last evaluated:
Feb 1, 2021
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000710140.4

Allele description [Variation Report for NM_001134407.3(GRIN2A):c.306C>T (p.Asp102=)]

NM_001134407.3(GRIN2A):c.306C>T (p.Asp102=)

Gene:
GRIN2A:glutamate ionotropic receptor NMDA type subunit 2A [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
16p13.2
Genomic location:
Preferred name:
NM_001134407.3(GRIN2A):c.306C>T (p.Asp102=)
HGVS:
  • NC_000016.10:g.10180106G>A
  • NG_011812.2:g.7649C>T
  • NM_000833.5:c.306C>T
  • NM_001134407.3:c.306C>TMANE SELECT
  • NM_001134408.2:c.306C>T
  • NP_000824.1:p.Asp102=
  • NP_001127879.1:p.Asp102=
  • NP_001127880.1:p.Asp102=
  • NC_000016.9:g.10273963G>A
  • NG_011812.1:g.7649C>T
  • NM_000833.3:c.306C>T
  • NM_000833.4:c.306C>T
  • p.Asp102Asp
Links:
dbSNP: rs200850130
NCBI 1000 Genomes Browser:
rs200850130
Molecular consequence:
  • NM_000833.5:c.306C>T - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_001134407.3:c.306C>T - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_001134408.2:c.306C>T - synonymous variant - [Sequence Ontology: SO:0001819]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000527650GeneDx
criteria provided, single submitter

(GeneDx Variant Classification Process June 2021)
Likely benign
(Feb 1, 2021)
germlineclinical testing

Citation Link,

SCV000613548Athena Diagnostics
criteria provided, single submitter

(Athena Diagnostics Criteria)
Benign
(Oct 25, 2017)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.

Karbassi I, Maston GA, Love A, DiVincenzo C, Braastad CD, Elzinga CD, Bright AR, Previte D, Zhang K, Rowland CM, McCarthy M, Lapierre JL, Dubois F, Medeiros KA, Batish SD, Jones J, Liaquat K, Hoffman CA, Jaremko M, Wang Z, Sun W, Buller-Burckle A, et al.

Hum Mutat. 2016 Jan;37(1):127-34. doi: 10.1002/humu.22918. Epub 2015 Oct 29.

PubMed [citation]
PMID:
26467025
PMCID:
PMC4737317

Details of each submission

From GeneDx, SCV000527650.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

From Athena Diagnostics, SCV000613548.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024